Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

NSCLC Stage IV Clinical Trial

Official title:

Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05281406
• Other study ID #: PACE LUNG
• Status: Recruiting
• Phase: Phase 2
• Start date: November 12, 2021
• Est. completion date: November 2026

Study information

• Verified date: May 2023
• Source: Goethe University
• Contact: Martin Sebastian, MD
• Phone: +49(0)69 6301
• Email: martin.sebastian[@]kgu.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

PACE is a prospective multicenter single-arm investigator-initiated phase II trial that examines the value of a treatment escalation strategy by the addition of platinum-based doublet chemotherapy to osimertinib in patients with treatment-naïve NSCLC harboring L858R or del19 EGFR mutation who are suspected to have poor response upon single-agent TKI treatment.

Description:

Hypothesize, that in patients with on-label osimertinib 1st-line treatment of stage IIIB or IV NSCLC, a biomarker-driven escalation of osimertinib therapy with a platinum-based chemotherapy regimen will effectively enhance PFS and subsequently OS. Lack of EGFRm clearance after an osimertinib treatment period of 3 weeks as assessed by liquid biopsy will be used to predict sub-optimal response. In these patients, treatment will be escalated after approx. 7 weeks of on-label osimertinib monotherapy by adding up to 4 cycles of a combination regimen of pemetrexed and cisplatin or carboplatin. Patients with complete EGFR plasma clearance will continue to receive standard of care osimertinib and will not be eligible for the study. Primary outcome measure will be PFS, which will be compared to historical data on TKI monotherapy from persistent EGFR shedder from the FLAURA trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: November 2026
• Est. primary completion date: November 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Pre-Screening Phase

1. Provision of written informed consent for the pre-screening phase.

2. Age = 18 years

3. Histologically confirmed stage IIIB or IV NSCLC

4. Tumor positive for Ex19del or L858R EGFR mutation assessed according to local standard.

5. Planned treatment with osimertinib 80mg/d 1st-line as SoC or ongoing treatment for a maximum of 28 days

6. Available radiographic chest and abdominal CT or MRI scans performed up to 42 days before initial osimertinib treatment

7. Previously untreated with systemic treatment given as primary therapy for advanced or metastatic disease, except for osimertinib for a maximum of 28 days (see above)

8. At least one measurable site of disease as defined by RECISTv1.1 criteria

9. Female subjects of childbearing potential (WOCBP) should be using highly effective contraceptive measures and must have a negative urine or serum pregnancy test within 7 days prior to start of study treatment and must not be breast-feeding prior to start of trial. Further information in Appendix 20.7 (Definition of Women of Childbearing Potential and Acceptable Contraceptive Methods)

10. Non-child-bearing potential must be evidenced by fulfilling one of the following criteria at screening:

• Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments

• Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution.

• Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation

Treatment Phase

1. Provision of informed consent for the screening and treatment phase prior to any study specific procedures, including screening evaluations that are not SoC.

2. Persistent mEGFR ctDNA signal 21 to 28 days after osimertinib initiation for advanced of metastatic ex19del or L858R EGFR mutation positive NSCLC as assessed by a liquid biopsy during the pre-screening phase of the trial in the central laboratory.

3. ECOG performance status 0-2.

4. The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations.

5. Osimertinib no longer than 10 weeks before start of chemotherapy in the treatment phase

Exclusion Criteria:

Pre-Screening Phase

1. History of another primary malignancy. Exceptions are:

• Malignancy treated with curative intent and with no known active disease =6 months before the first dose of IMP, and of low potential risk for recurrence

• Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease

• Adequately treated carcinoma in situ without evidence of disease

2. History of leptomeningeal carcinomatosis

3. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study, or during the follow-up period of an interventional study

4. Previous enrolment in the present study.

Treatment Phase

1. Symptomatic CNS metastases. [Patients with asymptomatic brain metastases may be included.]

2. History of leptomeningeal carcinomatosis

3. Currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 weeks prior) (Appendix 20.5). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4.

4. Osimertinib had to be withheld or administered at reduced dosage for toxicity management for more than 7 days or persistent unresolved toxicities which preclude study treatment.

5. Any unresolved toxicities other than osimertinib from prior therapy greater than CTCAE grade 1 at the time of starting study treatment, with the exception of alopecia and grade 2 prior platinum-therapy-related neuropathy.

6. History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib. History of hypersensitivity to any of the chemotherapy drugs used.

7. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.

8. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of osimertinib.

9. Any of the following cardiac criteria:

1. Mean resting corrected QT interval (QTc) > 470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value

2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block.

3. Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: Serum/plasma potassium < LLN; Serum/plasma magnesium < LLN; Serum/plasma calcium < LLN), congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes. [Note: Electrolyte abnormalities (hypokalaemia, hypomagnesaemia, hypocalcaemia) can be corrected to be within normal ranges prior to first dose. No more than two re-tests may be performed in order to meet this criterion.]

10. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.

11. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

1. Absolute neutrophil count below lower limit of normal (<LLN) *

2. Platelet count below lower limit of normal (<LLN) *

3. Hemoglobin <90 g/L *

• The use of granulocyte colony stimulating factor support, platelet transfusion and blood transfusions to meet these criteria is not permitted.

4. Alanine aminotransferase >2.5 times ULN if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases;

5. Aspartate aminotransferase >2.5 times ULN if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases;

6. Total bilirubin >1.5 times ULN if no liver metastases or >3 times ULN in the presence of documented Gilbert's Syndrome [unconjugated hyperbilirubinaemia] or liver metastases;

7. Serum creatinine >1.5 times ULN concurrent with creatinine clearance <60 mL/min [calculated by Cockcroft and Gault equation]-confirmation of creatinine clearance is only required when creatinine is >1.5 times ULN.

8. INR = 1.4 or aPTT = 40 sec during the last 7 days before chemotherapy [Subjects under therapeutic anticoagulation are permitted.]

12. Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.

13. Women who are pregnant or breast-feeding

14. Male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 4 months (male patients) or 6 weeks (female patients) after the last dose of osimertinib and 6 months after the last dose of chemotherapy.

15. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].

16. Treatment with an investigational drug within five half-lives of the compound or 3 months, whichever is greater.

17. Any chemotherapy, biologic, or hormonal therapy for cancer treatment used concurrently or within 6 months prior to first dose of study treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.

18. Major surgery (as defined by the Investigator) within 4 weeks prior to starting the study; patients must have recovered from effects of preceding major surgery. Note: Local non-major surgery for palliative intent (e.g., surgery of isolated lesions) is acceptable

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• NSCLC Stage IIIB
• NSCLC Stage IV

Intervention

Drug:
• Osimertinib
80 mg daily or reduced dose 40 mg daily
• Pemetrexed
500 mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
• Cisplatin
75mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
• Carboplatin
AUC 5 mg/mL/min i.v. d1 of every 21-day cycle for a maximum of 4 cycles

Locations

Country	Name	City	State
Germany	Charité Universitätsmedizin Berlin Campus Virchow Klinikum Klinik mit Schwerpunkt Infektiologie und Pneumologie	Berlin
Germany	Technische Universität Dresden Medizinische Fakultät Carl Gustav Carus Medizinische Klinik und Poliklinik I	Dresden
Germany	Universitätsklinikum Essen, Westdeutsches Tumorzentrum - Innere Klinik	Essen
Germany	University Hospital Frankfurt	Frankfurt
Germany	MVZ II der Niels Stensen Kliniken; Franziskus Hospital Harderberg	Georgsmarienhütte
Germany	Universitätsmedizin Göttingen, Klinik für Hämatologie und Medizinische Onkologie	Göttingen
Germany	Krankenhaus Martha-Maria Halle-Dölau Klinik für Innere Medizin II	Halle
Germany	Universitätsklinikum Hamburg-Eppendorf Hubertus Wald Tumorzentrum - UCCH II. Medizinische Klinik und Poliklinik	Hamburg
Germany	Universitätsklinikum Heidelberg, Thoraxklinik Heidelberg gGmbH	Heidelberg
Germany	Universitätsklinik Köln, Lung Cancer Group Cologne - Innere Medizin I	Köln
Germany	Universitätsmedizin der Johannes Gutenberg-Universität Mainz	Mainz
Germany	LMU-München Pneumologie und Thorakale Onkologie Medizinische Klinik V; Innenstadt	München
Germany	Klinikum Nürnberg Nord Paracelsus Med. Privat Universität Pneumologie und Lungentumorzentrum	Nürnberg
Germany	Pius Hospital Oldenburg Medizinischer Campus Universität Oldenburg	Oldenburg

Sponsors (1)

Lead Sponsor	Collaborator
Goethe University

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival (PFS1)	Progression Free Survival using investigator assessments according to Response Evaluation Criteria in Solid Tumours (RECIST 1.1) defined as number of months from first dose of chemotherapy until last follow-up, PD, death or withdrawal of consent.	2 years
Secondary	Progression Free Survival (PFS0)	Progression Free Survival using investigator assessments according to Response Evaluation Criteria in Solid Tumours (RECIST 1.1) defined as number of months from first dose of osimertinib until last follow-up, PD, death or withdrawal of consent.	for a minimum of 24 months from inclusion
Secondary	Overall Survival (OS1)	OS1 Survival will be calculated from the first dose of chemotherapy until the date of death from any cause. If no event is observed (e.g. lost to follow-up) OS is censored at the day of last subject contact.	for a minimum of 24 months from inclusion
Secondary	Overall Survival (OS0)	OS0 Survival will be calculated from the date of start of osimertinib until the date of death from any cause. If no event is observed (e.g. lost to follow-up) OS is censored at the day of last subject contact.	for a minimum of 24 months from inclusion
Secondary	Incidence of treatment related Adverse Events (Safety and Tolerability)	Frequency and severity of Adverse Events, grading according to CTCAE V5.0	up to 16 weeks from start of study treatment
Secondary	Measurement of Quality of Life with PRO-CTCAE. questionnaire	Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) minimum value: not at all (1); maximum value: severe (5); higher scores mean a worse outcome	up to 16 weeks from start of study treatment
Secondary	Measurement of Quality of Life with EORTC QLQ-C30 questionnaire	The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) minimum value: not at all (1); maximum value: very much (4); higher scores mean a worse outcome	up to 16 weeks from start of study treatment